Thanks, Jason. So, I’m going to start out, provide a little color on the quarter, also talk about some things we’re working on and how we kind of are looking into next year. I have some prepared comments that I’m going to touch on. I’m also going to go off script a little bit. I came out to my office this morning, I haven’t really thought about it before this morning, and I think if I’m right, this is my 84th earnings call. So, this week, on my 22nd anniversary with the company, 21 years since I took over in November of 2004. So, a bunch of these.

You know what, I’ve looked at our stock as the market opened, and I was a little bit surprised at the reaction frankly.  I want to hit on some highlights. I want to talk about what we’re working on, and how we would look at things going forward. So, I think we’re looking at things maybe a little bit differently, but volume has continued to be strong for us in the quarter. We’re up 18%, but certainly a bunch of that is Metro, which you know, we completed that acquisition in November. It was November of last year. We’re doing great, but what I want to point out is we’ve added a total of 84 PT facilities, so a lot more than just Metro in this last year, and that’s 84, net, but we’ve added actually more than that and that number’s net of closures. But, this last quarter, visits per clinic per day produced a new record for us for Q3 to 32.2, underscoring our ability to continue to grow.

You know what’s driving all that is the care and the service and the amazing connections that our clinical people are making every day, not just the clinical people, but the people who greet our patients as they come in the door. Patients come in, they’re in pain, they’re frightened, and in some cases, they’re worried about the ability to do the things they’ve always done. As I mentioned in the last earnings call, last quarter, our net promoter score is over 90, almost mid-90s, across our entire company for our patients and our out-patient facilities. Just incredible. So, look, none of this is perfect at any given point, but we are making a difference in a lot of patients’ lives. Those patients recognize the value and the service they’re getting from us. They pay their bills, collect their money, and then we get them back later when pickleball happens, or there’s something else that causes their function to be impacted.

This quarter, again, maybe it’s against the soft quarter a year ago a bit, but gross profit grew 30%. I haven’t seen those numbers in a long time, even if you just add some of the noise from a year ago, still mid-teens gross profit increase number for PT, and that’s in the middle of an inflationary period and a period where staff is more expensive. We impacted our salary and related cost per visit on a year-over-year basis and actually went down some. We’re working on a number of initiatives including AI-driven documentation, including what I refer to as the semi-virtualization of our front desk operations, and that’s rolling out. We have a target for that by year end of 200 facilities, about halfway there, but we’re beginning to see some impact from both of those things, and we’ve got more to come. We’re just on the front-end of a number of these things, which takes some time.

If we look at the year, one of the big headwinds we’ve been faced with quite honestly now for five years is this Medicare headwind. CMS produced the final rule on Friday. It came out as it often does and there were some incorrect tables in our part of the rule that we had to contact CMS about, and it took them a couple of days. They looked at it. In fact, they were incorrect.  They’ve updated those tables. It’s got a little bit better than the last time we talked. I think the last time – and we’re not done with our analysis. Last time, we said it was going to be about a 1.5% increase, probably a little better than that right now. This year’s more complicated than most because of the significance and the change in the geographic index factors that kind of shuffled all around the country.

One of the things that swung for us was that the net positive reimbursement for manual therapy, which is when we put our hands on our patients when we mobilize joints, when we restore motion, again, through that very upfront and close personal contact, in very precise ways. We do that on almost every patient that comes in the door. Manual therapy was slated to go down. We challenged their assumptions, and in this final rule, manual therapy will go up slightly. So, it reversed from the negative to a slight positive. So, that’s positive for us as we re-sort the impact of this final rule.

The other thing that I think will be meaningfully positive is that in 2024, we went and began to roll out remote therapeutic monitoring, which was a new code for us, and the rules around that code - I’m not going to go through all of it, but it required a lot of visits and a lot of monitoring which we did with the partner, Limber. Great guys and they’ve done a great job, but it was clunky. Took a little while, we had to integrate Limber’s tool into our EMR system that took some considerable time, wasn’t within our control frankly, and by the end of the year, we hadn’t gotten the traction with our partnerships that we had hoped. Now, what CMS has appreciated, which is what we’ve appreciated, that the patients who go through and have as part of their care remote therapeutic monitoring actually get better outcomes, they’re more engaged with their home program, and they’re more adherent to their total program which helps them to regain function.

So, CMS, again, with encouragement from groups like APTQI and others, they’ve reduced significantly the number of visits that it takes in order to get to a billable code. We now have a fully integrated working model through an app which integrates well with our EMR, and so beginning 2026, this will be a reinitiation of that opportunity for us which we’re just right now, skimming the surface of. So, for the first time in a while, we’re going to see some blue sky in 2026, particularly in terms of our Medicare reimbursement. We see additional opportunities around remote therapeutic monitoring, and then we’ve got these internal initiatives to help with our efficiency, and our patient flow and our cost overall. So, that’s very encouraging.

I want to shift the gear a minute and talk a little bit about our injury prevention business. Both of those teams are doing really well this year. I’ve read in one of the analyst reports that injury prevention for the quarter was disappointing. Look, this quarter, we’ve lapped an acquisition that we had in the last quarter which gave us mid-20s revenue growth. If I remember right, it's 14%, 15% this quarter. That's purely organic. Still strong revenue growth. That's where we've been. We've got other injury prevention opportunities in the pipeline. We continue to love this business. Deals happen when we get them done. We don't talk about them, and we don't put information out ahead of time. But you're going to continue to see us grow this business because we have high confidence in our teams in both injury prevention partnerships. We have other things in the market that we like that we think are going to be impactful, help us to grow our industry verticals and help us to grow our service opportunities. We started this in 2017, and we had a great team, but we had a very small company, very narrow service line. The service lines have broadened significantly over the years. Teams got even stronger and our industry verticals have gotten wider and wider as we've added more programs and services. You're going to see that continue to be a strong focus for us.

Let me just say this in closing. I know I touched on a number of things. This is a team that doesn't give up. We've had a lot of headwinds over the years. It's been challenging. We always find a way. If you look at the Medicare cuts that we've absorbed in these last few years, it aggregates over 11%. If you look at the impact just in this year, it's a $25 million cumulative profit impact. Yet we found a way throughout all those years to continue to grow. Now that Medicare headwinds are going to be gone, we have some good things in the mix. We still have great capital structure, and we have a very, very strong resolve to take this company forward and do the things that we've said we're going to do.

With that, I'm going to turn it over to Carey to cover the details and we look forward to your questions. Thank you.